David Mou, MD, was appointed as Mr. Robertson’s replacement, the report said. Dr. Mou is Cerebral’s president and chief medical officer.
The company had paused controlled substances prescriptions for new patients earlier in the week, and some retail pharmacies stopped filling Cerebral prescriptions for Adderall, a stimulant used to treat ADHD.
At the Becker's Fall Behavioral Health Summit, taking place October 20–22 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
